ABSTRACT
BACKGROUND: Treatment with apremilast has recently demonstrated clinically meaningful improvement in moderate hidradenitis suppurativa (HS). OBJECTIVE: To evaluate the change in expression of inflammatory markers in lesional skin of HS patients receiving apremilast 30 mg twice daily (n = 15) for 16 weeks compared with placebo (n = 5). METHODS: At baseline, 5-mm punch biopsies were obtained from an index lesion (HSL) and non-lesional (HSN) skin in the same anatomical area. Subsequent HSL samples were taken as close as possible to the previously biopsied site at week 4 and week 16. After sampling, biopsies were split; one half was processed for in vivo mRNA analysis using real-time quantitative PCR; the other half was cultured for ex vivo protein analysis using a proximity extension assay (Olink). Linear mixed effects models were calculated to compare the levels of inflammatory markers in HSL skin between apremilast and placebo over time. RESULTS: At baseline, 17 proteins with a fold change >2 in HSL vs. HSN skin were identified in 20 patients. The top five were IL-17A (5), S100A12, CST5, IL-12/23p40, CD6 (1) with fold changes ranging from 6.6 to 1638, respectively (FDR <0.044). Linear mixed effects models for 75 assays were calculated. Protein levels of S100A12 decreased during treatment in the apremilast group compared with the placebo group (p = 0.014, FDR = 0.186). None of the 14 genes exhibited significant changes in expression over time. However, an evident downward trend in relative mRNA expression of IL-17A and IL-17F was demonstrated in patients receiving apremilast. CONCLUSION: We did not detect statistically significant changes in inflammatory markers in HSL skin of HS patients receiving apremilast compared with placebo, despite clinical improvement in the apremilast group. Nonetheless, S100A12 and IL-17A were significantly elevated in HSL skin and showed a decrease in response to apremilast. The translational model in clinical trials involving HS clearly needs further improvement.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Hidradenitis Suppurativa/drug therapy , Hidradenitis Suppurativa/metabolism , RNA, Messenger/metabolism , Thalidomide/analogs & derivatives , Adult , Antigens, CD/genetics , Antigens, CD/metabolism , Antigens, Differentiation, T-Lymphocyte/genetics , Antigens, Differentiation, T-Lymphocyte/metabolism , Biomarkers/metabolism , Cystatins/genetics , Cystatins/metabolism , Female , Hidradenitis Suppurativa/genetics , Humans , Interleukin-12/genetics , Interleukin-12/metabolism , Interleukin-17/genetics , Interleukin-17/metabolism , Male , Middle Aged , S100A12 Protein/genetics , S100A12 Protein/metabolism , Thalidomide/therapeutic use , Young AdultABSTRACT
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease mainly affecting synovial joints. The clinical presentation of RA shows the heterogeneity of this disease with its underlying complex interactions between the innate and adaptive immune system and flare-ups of disease. Different disease models such as collagen induced arthritis, antigen induced arthritis, and Streptococcal cell wall induced arthritis can be exploited to investigate different aspects of the pathogenesis of arthritis. The disease can be monitored macroscopically over time via scoring systems. For histological examination, paraffin embedded knee sections can be used for hematoxylin and eosin staining to visualize cellular infiltration as well as for tartrate-resistant acid phosphatase (TRAP) staining to identify osteoclast-like cells. Cellular infiltration of the synovium by different myeloid cells such as tissue resident macrophages, dendritic cells and neutrophils can be monitored using flow cytometry. Here, we describe the methods for inducing the different mouse models for arthritis, including scoring systems per model, histological and flow cytometric analysis.
Subject(s)
Adaptive Immunity , Arthritis, Experimental/immunology , Cartilage, Articular/immunology , Disease Models, Animal , Immunity, Innate , Myeloid Cells/immunology , Animals , Arthritis, Experimental/chemically induced , Arthritis, Experimental/pathology , Biomarkers/metabolism , Cartilage, Articular/pathology , Cell Wall/chemistry , Collagen/administration & dosage , Complex Mixtures/administration & dosage , Female , Flow Cytometry/methods , Freund's Adjuvant/administration & dosage , Gene Expression , Injections, Intra-Articular , Male , Mice , Mice, Inbred C57BL , Myeloid Cells/pathology , Serum Albumin, Bovine/administration & dosage , Streptococcus/chemistry , Tartrate-Resistant Acid Phosphatase/genetics , Tartrate-Resistant Acid Phosphatase/immunologyABSTRACT
OBJECTIVE: Both Th1 cells and Th17 cells have been recognized in rheumatoid arthritis (RA); however, it remains unclear whether Th1 cells and/or Th17 cells are involved in driving disease chronicity and destructiveness. The aim of this study was to identify and characterize the functional role of Th17 cells in early RA. METHODS: Flow cytometry analysis was performed on peripheral blood mononuclear cells (PBMCs) from treatment-naive patients with early RA and age-matched healthy volunteers. PBMCs from these patients, naive T cells, and primary CCR6- Th1 cells and CCR6+ Th17 cells were sorted and cultured in the absence or presence of synovial fibroblasts from patients with early RA (RASFs), and cytokine expression and gene transcription were analyzed. In addition, tumor necrosis factor α (TNFα)- and interleukin-17A (IL-17A)-blocking experiments were performed. RESULTS: In the PBMCs of treatment-naive patients with early RA, an increased fraction of IL-17A-and TNFα-producing CCR6+ Th17 cells was observed. When cocultured with RASFs, these primary Th17 cells were potent inducers of IL-6 and IL-8 and the tissue-destructive enzymes matrix metalloproteinase 1 (MMP-1) and MMP-3, whereas primary Th1 cells or naive T cells were not. Importantly, specific up-regulation of IL-17A but not TNFα or interferon-γ was observed in RASF/Th17 cell cocultures. In addition to TNFα blocking, IL-17A neutralization was required to further down-regulate Th17 activity in RASF/Th17 cell cocultures. CONCLUSION: Th17 cells, but not Th1 cells, cooperated with RASFs in a proinflammatory feedback loop, revealing a potential mechanism by which human Th17 cells drive chronic destructive disease in patients with RA. Furthermore, the neutralization of IL-17A activity is essential in current anti-TNF therapies to suppress Th17 cell activity in patients with early RA and potentially other Th17 cell-mediated disorders.
Subject(s)
Arthritis, Rheumatoid/metabolism , Cytokines/metabolism , Interleukin-17/biosynthesis , Matrix Metalloproteinases/metabolism , Synovial Membrane/metabolism , Th1 Cells/metabolism , Th17 Cells/metabolism , Adult , Arthritis, Rheumatoid/immunology , Autocrine Communication/immunology , Cells, Cultured , Cytokines/immunology , Female , Fibroblasts/immunology , Fibroblasts/metabolism , Flow Cytometry , Humans , Inflammation/immunology , Inflammation/metabolism , Interleukin-17/immunology , Leukocytes, Mononuclear/immunology , Leukocytes, Mononuclear/metabolism , Male , Matrix Metalloproteinases/immunology , Middle Aged , Reverse Transcriptase Polymerase Chain Reaction , Statistics, Nonparametric , Synovial Membrane/immunology , Th1 Cells/immunology , Th17 Cells/immunologyABSTRACT
OBJECTIVE: To examine the immunologic mechanism by which 1,25-dihydroxyvitamin D(3) (1,25[OH](2)D(3)) may prevent corticosteroid-induced osteoporosis in patients with early rheumatoid arthritis (RA), with a focus on T cell biology. METHODS: Peripheral blood mononuclear cells (PBMCs) and CD4+CD45RO+ (memory) and CD4+CD45RO- (non-memory) T cells separated by fluorescence-activated cell sorting (FACS) from treatment-naive patients with early RA were stimulated with anti-CD3/anti-CD28 in the absence or presence of various concentrations of 1,25(OH)(2)D(3), dexamethasone (DEX), and 1,25(OH)(2)D(3) and DEX combined. Levels of T cell cytokines were determined by enzyme-linked immunosorbent assay and flow cytometry. RESULTS: The presence of 1,25(OH)(2)D(3) reduced interleukin-17A (IL-17A) and interferon-gamma levels and increased IL-4 levels in stimulated PBMCs from treatment-naive patients with early RA. In addition, 1,25(OH)(2)D(3) had favorable effects on tumor necrosis factor alpha (TNFalpha):IL-4 and IL-17A:IL-4 ratios and prevented the unfavorable effects of DEX on these ratios. Enhanced percentages of IL-17A- and IL-22-expressing CD4+ T cells and IL-17A-expressing memory T cells were observed in PBMCs from treatment-naive patients with early RA as compared with healthy controls. Of note, we found no difference in the percentage of CD45RO+ and CD45RO- cells between these 2 groups. Interestingly, 1,25(OH)(2)D(3), in contrast to DEX, directly modulated human Th17 polarization, accompanied by suppression of IL-17A, IL-17F, TNFalpha, and IL-22 production by memory T cells sorted by FACS from patients with early RA. CONCLUSION: These data indicate that 1,25(OH)(2)D(3) may contribute its bone-sparing effects in RA patients taking corticosteroids by the modulation of Th17 polarization, inhibition of Th17 cytokines, and stimulation of IL-4.
Subject(s)
Arthritis, Rheumatoid/immunology , CD4-Positive T-Lymphocytes/drug effects , Calcitriol/pharmacology , Immunologic Memory , Interleukins/metabolism , Adult , Aged , Antibodies, Monoclonal/pharmacology , Arthritis, Rheumatoid/blood , CD28 Antigens/immunology , CD3 Complex/immunology , CD4-Positive T-Lymphocytes/immunology , Cell Polarity/drug effects , Cell Polarity/immunology , Cell Separation , Dexamethasone/pharmacology , Drug Combinations , Female , Flow Cytometry , Humans , Interleukin-17/metabolism , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/immunology , Male , Middle Aged , Young Adult , Interleukin-22ABSTRACT
We report the case of a unilateral traumatic thrombosis of the renal artery. Revascularization was not performed because the diagnosis was made more than 24 h after the injury. Early diagnosis and prompt surgical repair are the keys to successful management of this complication.
Subject(s)
Aortography , Renal Artery Obstruction/diagnostic imaging , Renal Artery/injuries , Thrombosis/diagnostic imaging , Tomography, X-Ray Computed , Wounds, Nonpenetrating/diagnostic imaging , Adolescent , Follow-Up Studies , Humans , Infarction/diagnostic imaging , Kidney/blood supply , Male , Postoperative Complications/diagnostic imaging , Renal Artery/diagnostic imagingABSTRACT
Report on 2 cases of urological neoplasia in HIV positive patients. The first one is a renal adenocarcinoma in a heroin-abuser patient, of a type we have only found mentioned in the literature in 4 other cases. The second case was a disseminated Kaposi's sarcoma, the first symptom being a scrotum impairment and the biopsy suggested the diagnosis. This is believed to be an interesting communication considering the increasing number of anti-HIV antibodies carriers seen in our Units.